A phase Ib/II trial with expansion of patients at the MTD trial of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.

Saul E. Rivkin,Desiree Iriarte,Heather L. Sloan,Cara Wiseman,James J. Moon,Gary E. Goodman,Amy E. Bondurant,Daniel Veljovich,Peter Jiang,Tanya A. Wahl,Chirag A. Shah,Charles W. Drescher,Henry G. Kaplan,William A. Peters,Erin Ellis,Mehmet F. Fer,Min S. Park,Eileen Johnston

A phase Ib/II trial with expansion of patients at the MTD trial of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.

2014

Saul E. Rivkin
Desiree Iriarte
Heather L. Sloan
Cara Wiseman
James J. Moon
Gary E. Goodman
Amy E. Bondurant
Daniel Veljovich
Peter Jiang
Tanya A. Wahl
Chirag A. Shah
Charles W. Drescher
Henry G. Kaplan
William A. Peters
Erin Ellis
Mehmet F. Fer
Min S. Park
Eileen Johnston

5527 Background: To establish the maximum-tolerated dose (MTD) and evaluate dose-limiting toxicities (DLTs) and response to therapy of combination therapy with carboplatin/paclitaxel and olaparib, ...

Keywords:

Ovarian cancer
Cancer research
Carboplatin
Physical therapy
Olaparib
Paclitaxel
Medicine
Combination therapy
response to therapy
Oncology
Pathology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations